Cyclo Therapeutics Inc. (NASDAQ: CYTH)
$0.5990
-0.0030 ( +1.53% ) 30.6K
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
Market Data
Open
$0.5990
Previous close
$0.6020
Volume
30.6K
Market cap
$16.53M
Day range
$0.5690 - $0.6300
52 week range
$0.5690 - $2.1150
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Nov 18, 2024 |
10-q | Quarterly Reports | 63 | Nov 14, 2024 |
8-k | 8K-related | 16 | Nov 08, 2024 |
8-k | 8K-related | 14 | Oct 09, 2024 |
8-k | 8K-related | 17 | Oct 08, 2024 |
8-k | 8K-related | 16 | Sep 09, 2024 |
8-k | 8K-related | 23 | Aug 22, 2024 |
4 | Insider transactions | 1 | Aug 20, 2024 |
4 | Insider transactions | 1 | Aug 20, 2024 |
4 | Insider transactions | 1 | Aug 20, 2024 |